治疗用脐血干细胞的制备及初步临床应用

目的制备满足临床干细胞治疗需要的脐带血干细胞制剂,观察脐血干细胞局部移植治疗肝硬化失代偿和股骨头坏死的初步临床疗效。方法建立标准化操作规程(SOP),进行脐带血的采集、分离和检测,制备脐带血干细胞制剂进行局部移植。选择进行局部移植干细胞制剂治疗的相关疾病患者共11例,其中肝硬化9例、股骨头缺血坏死2例;年龄30—65岁,平均51岁,男9例,女2例。结果制备的脐带血干细胞制剂有核细胞计数达(3.8±1.73)×109个,均达到治疗剂量,其中CD34+细胞比率为(1.93±0.54)%,CD105+细胞比率为(97.9±4.0)%。肝硬化失代偿期患者治疗后白蛋白水平逐步升高,1个月后与治疗前相比有明显升高(P<0.05)。肝硬化和股骨头缺血坏死患者经治疗后临床症状均有好转。结论脐带血干细胞移植可为临床多种疾病的有效治疗提供一种新手段。

Preparation of umbilical cord blood stem cells and preliminary clinical application

Objective To prepare umbilical cord blood (UCB) stem cells for clinical local transplantation,and to investigate the therapeutic effect on patients with decompensated liver cirrhosis and femoral head necrosis.Methods Stem cells from UCB units were collected,separated and identified.Eleven patients aged 30 to 65 years (average 51 years) from March to November in 2009 were treated by stem cell transplantation.Among them,9 patients suffered from decompensated liver cirrhosis and 2 patients had femoral head necrosis.Liver function tests before and after the stem cell therapy were performed Results The average number of total nucleated cells of the stem cell unit was(3.8±1.73)×109,which was over the therapeutic dose.The percentage of CD34+ was(1.93±0.54)%,and CD105+ was(97.9±4.0)%.After transplantation,levels of albumin were increased,especially one month later(P<0.05).Clinical symptoms of patients with decompensated liver cirrhosis and femoral head necrosis were improved.Evaluation of long-term efficacy was continuing.Conclusion Using stem cells from UCB may provide a new tool for the treatment of patients with various diseases.